| Literature DB >> 29295497 |
María José Bagur1,2, Gonzalo Luis Alonso Salinas3, Antonia M Jiménez-Monreal4, Soukaina Chaouqi5,6, Silvia Llorens7, Magdalena Martínez-Tomé4, Gonzalo L Alonso8.
Abstract
The spice saffron is made from the dried stigmas of the plant Crocus sativus L. The main use of saffron is in cooking, due to its ability to impart colour, flavour and aroma to foods and beverages. However, from time immemorial it has also been considered a medicinal plant because it possesses therapeutic properties, as illustrated in paintings found on the island of Santorini, dated 1627 BC. It is included in Catalogues of Medicinal Plants and in the European Pharmacopoeias, being part of a great number of compounded formulas from the 16th to the 20th centuries. The medicinal and pharmaceutical uses of this plant largely disappeared with the advent of synthetic chemistry-produced drugs. However, in recent years there has been growing interest in demonstrating saffron's already known bioactivity, which is attributed to the main components-crocetin and its glycosidic esters, called crocins, and safranal-and to the synergy between the compounds present in the spice. The objective of this work was to provide an updated and critical review of the research on the therapeutic properties of saffron, including activity on the nervous and cardiovascular systems, in the liver, its antidepressant, anxiolytic and antineoplastic properties, as well as its potential use as a functional food or nutraceutical.Entities:
Keywords: crocetin esters; crocin; functional food; nutraceutical; picrocrocin; saffron; safranal; therapeutic properties
Mesh:
Substances:
Year: 2017 PMID: 29295497 PMCID: PMC5943931 DOI: 10.3390/molecules23010030
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structures of crocetin (A), picrocrocin (B) and safranal (C).
Figure 2Simplified name of the glycosidic esters, crocins, of the carotenoid crocetin introduced by Carmona and coworkers [22]. Meaning of the abbreviations: t is triglucose; G is gentiobiose; n is neapolitanose; g is glucose.
Summary of the clinical trials found in the literature. The supplied agent is indicated, if an analysis of its composition has been carried out, time in weeks of application, dose in mg/day, demonstrated bioactivity and reference.
| Agent Supplied | Analysis Comp. | Time (Week) | Dose (mg/day) | Bioactivity | Ref. |
|---|---|---|---|---|---|
| Saffron ethanol (80%) extract | Bad analysis | 16 | 30 | Alzheimer‘s disease | [ |
| Saffron ethanol (80%) extract | Bad analysis | 22 | 30 | Alzheimer‘s disease | [ |
| Saffron ethanol (80%) extract | Bad analysis | 48 | 30 | Alzheimer‘s disease | [ |
| Yes | undefined | 0.25 | Glioblastoma | [ | |
| Saffron | Yes | 12 | 20 | Macular degeneration | [ |
| Saffron | No | 56 | 20 | Macular degeneration | [ |
| Saffron | No | 12 | 20 | Macular degeneration | [ |
| Saffron aqueous extract (SAE) and crocin (CR) | Yes | 12 | SAE: 30 | Schizophrenia | [ |
| Saffron ethanol (80%) extract | No | 6 | 30 | Depression | [ |
| Saffron ethanol (80%) extract | No | 6 | 30 | Depression | [ |
| Saffron ethanol (80%) extract | No | 6 | 30 | Depression | [ |
| Saffron ethanol (80%) extract | No | 6 | 30 | Depression | [ |
| Crystallized crocin | No | 4 | 30 | Depression | [ |
| Saffron | No | 6 | 30 | Depression | [ |
| Saffron ethanol (80%) extract | No | 8 | 30 | Premenstrual syndrome | [ |
| Saffron | Yes | 12 | 50 | Lipid Profile | [ |